Severe asthma is a compelling challenge in clinical practice. Adolescence represents a relevant aspect of this issue. We report a series of adolescents with severe asthma and evaluated before and after a one-year standardized guideline-oriented treatment. We explored the relevance of symptom perception, including nasal and bronchial complaints, assessed by visual analog scale (VAS) and the perception of asthma control measured by the asthma control test (ACT). The current study demonstrated that adolescents perceived a significant improvement in their symptoms (p < 0.0001) and asthma control (p < 0.001) after adequate treatment. In conclusion, the management of severe asthma in adolescents should be carefully addressed to also consider the patient's perception.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.aller.2019.10.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Co-exposure to polyethylene microplastics and house dust mites aggravates airway epithelial barrier dysfunction and airway inflammation via CXCL1 signaling pathway in a mouse model.
Int Immunopharmacol
December 2024
Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Department of Allergy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. Electronic address:
Background: Environmental pollutants have been found to contribute to the development and acute exacerbation of asthma. Microplastics (MPs) have received widespread attention as an emerging global pollutant. Airborne MPs can cause various adverse health effects.
View Article and Find Full Text PDFIntroduction: The article discusses topical issues of the use of conjugated 13-valent pneumococcal vaccine Prevenar®13 (PCV13) in patients with severe bronchial asthma (SBA), including those receiving targeted therapy with genetically engineered biological drugs (GEBD).
Aim: To study the effectiveness of vaccination against pneumococcal infection (PI) in patients with SBA.
Materials And Methods: The study included 381 patients with SBA.
Insomnia during the COVID-19 pandemic: prevalence and correlates in a multi-ethnic population Singapore.
BMC Public Health
December 2024
Research Division, Institute of Mental Health, 10 Buangkok View, Buangkok Green, Medical Park, Singapore, 7539747, Singapore.
Background: Globally, the Coronavirus disease 2019 (COVID-19) pandemic had a significant impact on mental health. Sudden lifestyle changes, threatening information received through various sources, fear of infection and other stressors led to sleep disturbances such as insomnia. The current study aimed to assess the prevalence of insomnia and its associated risk factors during the first wave of COVID-19 pandemic among Singapore residents.
View Article and Find Full Text PDFPsychiatric disorders in children and adolescents with temporal lobe epilepsy: A narrative review.
Epilepsia Open
December 2024
University of Florence, Florence, Italy.
People with epilepsy (PWE) are at higher risk of psychiatric disorders (PD), disability, and reduced quality of life than the general population, especially in childhood and adolescence and when seizures originate from the temporal lobe. Temporal Lobe Epilepsy (TLE) is the most common type of focal epilepsy and can be due to structural abnormalities, or non-lesional causes, such as genetic variants. The prevalence of PD is approximately 20%-30% in people with epilepsy in general, and from 40% up to 80% in people with TLE.
View Article and Find Full Text PDFA novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases.
Front Immunol
December 2024
Tavotek Biotherapeutics, Inc., Lower Gwynedd Township, PA, United States.
Introduction: Thymic stromal lymphopoietin (TSLP) is a master regulator of allergic inflammation against pathogens at barrier surfaces of the lung, skin, and gut. However, aberrant TSLP activity is implicated in various allergic, chronic inflammation and autoimmune diseases and cancers. Biologics drugs neutralizing excess TSLP activity represented by tezepelumab have been approved for severe asthma and are being evaluated for the treatments of other TSLP-mediated diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!